Reported trial results for Castleman Disease

3 trials have reported results.

AI generated results summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

• NCT04585893 · results posted 11 September 2025

  According to the results reported on ClinicalTrials.gov, a total of 15 people took part in this trial — 9 classified as "high-risk" and 6 classified as "low-risk." The trial was studying a treatment approach for Multicentric Castleman disease (MCD), a rare condition affecting the lymph nodes, in Malawi. The trial divided participants into two groups based on their risk level and gave each group a different treatment suited to their risk category. Of the 15 who started, 14 completed the study (8 high-risk and 6 low-risk), with one high-risk participant not completing it. The reported data shows that the main (primary) outcome being tracked was the number of participants who experienced serious side effects — specifically, non-blood-related side effects rated at a severity level of "grade 3" or above (meaning severe, life-threatening, or fatal, according to a standard medical grading system). According to the results reported on ClinicalTrials.gov, zero participants in either the high-risk group or the low-risk group were reported to have experienced this level of serious side effect. The reported data shows that several secondary outcomes — including overall survival (how long participants lived), event-free survival (how long they went without signs of disease returning), clinical response rate (how many participants saw their symptoms resolve), and a description of how the disease presented in Malawi — were listed as planned measurements, but no numerical results for these outcomes were reported in the submitted data. These are the results as reported to ClinicalTrials.gov. They are not medical advice — always discuss what they mean for you with your doctor.

  Read the full trial page · View reported results on ClinicalTrials.gov ↗

• NCT01400503 · results posted 29 March 2018

  According to the results reported on ClinicalTrials.gov, this trial enrolled 60 participants, all of whom received a medicine called siltuximab. The trial was a long-term safety extension study, meaning its main purpose was to track unwanted medical events (called adverse events) that occurred while participants were receiving the treatment. The reported data shows that none of the 60 participants were recorded as having "completed" the study in the usual sense — all 60 were listed under "not completed," which may reflect the nature of a long-term extension study, though no further explanation for this was provided in the data. The reported data shows that all 60 participants experienced at least one adverse event during the study. For the secondary measures, the results were broken into two groups: participants who had previously responded to siltuximab before joining this extension, and those who were new to the medicine. Among those who had previously responded, 96.5% were reported to have maintained what the study called "disease control" (meaning their condition stayed stable or improved, as judged by their doctor). Among those who were new to siltuximab, 100% were reported to have experienced disease control during the study. Additionally, 3 out of 60 participants were found to have developed antibodies to siltuximab (proteins the body can produce in response to a medicine). Two other measures — how long disease control lasted and overall survival — were listed but no figures were reported in the data submitted. These are the results as reported to ClinicalTrials.gov. They are not medical advice — always discuss what they mean for you with your doctor.

  Read the full trial page · View reported results on ClinicalTrials.gov ↗

• NCT01024036 · results posted 20 August 2014

  According to the results reported on ClinicalTrials.gov, this trial looked at a condition called multicentric Castleman's disease, which is a rare disorder affecting the lymph nodes. A total of 79 people took part — 53 received a medicine called siltuximab alongside best supportive care (standard care aimed at managing symptoms), and 26 received a placebo (a dummy treatment) alongside best supportive care. The trial's main goal was to measure how many participants had a meaningful and lasting shrinkage of their disease along with an improvement in symptoms, sustained for at least 18 weeks. The reported data shows that, for the main outcome, 34% of participants in the siltuximab group met the criteria for this combined tumour and symptom response, compared with 0% in the placebo group. For the secondary outcomes, the reported data shows that among those in the siltuximab group who did respond, the median time they maintained that response was 383 days (roughly 13 months). Looking at tumour shrinkage alone (without the symptom requirement), 37.7% of the siltuximab group and 3.8% of the placebo group met the criteria, with a median duration of 356 days versus 70 days respectively. The trial also tracked how long it was before treatment was considered to have stopped working — the reported figure for the placebo group was 134 days, while a median figure for the siltuximab group was not reached during the study period. Additionally, 61.3% of participants in the siltuximab group and 0% in the placebo group reached a pre-specified increase in haemoglobin (a measure of red blood cells) by week 13; this figure for the placebo group was not reported separately for the duration outcome. These are the results as reported to ClinicalTrials.gov. They are not medical advice — always discuss what they mean for you with your doctor.

  Read the full trial page · View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗

See the full Castleman Disease page · What changed recently

Not medical advice. These are results as reported by the trial sponsor to a public registry, summarised in plain English. They describe what a trial recorded, not whether a treatment is suitable for any person. Verify anything important against the original registry record and discuss what it means for you with your doctor.